Don't Yet Rely on Bezlotoxumab to Lower Risk of Recurrent C. diff Diarrhea

You'll hear about bezlotoxumab (Zinplava, zin-PLAH-vah), the first drug approved to prevent DIARRHEA recurrence due to Clostridium difficile.

Around one in 4 patients will have a recurrence of C. diff diarrhea after the first episode...and 2 in 3 after the second episode.

Bezlotoxumab is a monoclonal antibody that binds to C. diff's toxin keep its diarrhea-causing effects from returning.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals